Engineered E. coli Produces Key Compounds for Cancer, HIV & More

Researchers at Kobe University in Japan have achieved a significant breakthrough in the production of complex pharmaceutical compounds, successfully engineering E. Coli bacteria to synthesize orsellinic acid – a key building block for a range of drugs with anticancer, anti-HIV, antidiabetic, and anti-inflammatory properties. The accomplishment, detailed in the journal Metabolic Engineering, represents a 40-fold increase in production yield compared to previous microbial attempts and marks the first successful synthesis of orsellinic acid within E. Coli.

The challenge addressed by the Kobe University team stems from the inherent difficulties in sourcing these valuable compounds from their natural origins. Many promising pharmacological agents are produced by plants, such as species of Rhododendron, which generate orsellinic acid-derived meroterpenoids. However, relying on plant extraction is often unstable, costly, and unsustainable. Previous efforts to coax microbes into producing orsellinic acid yielded disappointingly low quantities, hindering research and potential industrial applications.

“There are many examples where compounds appear promising in the literature but fail to advance sufficiently in evaluation or applied research due to supply issues,” explains Tomita Itsuki, a doctoral student at Kobe University and the study’s first author. “I began to feel Here’s less an issue with individual compounds and more a structural challenge facing natural products research as a whole.”

The team, led by bioengineer Hasunuma Tomohisa, employed a rational design strategy, combining genetic engineering with metabolic analysis and optimization of culture conditions. This involved introducing specific genes from plants, fungi, and bacteria into E. Coli, effectively reconstructing the complex biosynthetic pathway required to produce orsellinic acid. E. Coli was chosen for its well-understood genetics and its established role as a workhorse in industrial biotechnology.

The resulting engineered bacteria achieved a production level of 202 mg of orsellinic acid per liter. This substantial improvement opens the door to more efficient and scalable production of this crucial compound. “This proves a significant achievement that we recreated a complex eukaryotic biosynthetic pathway in the bacterium E. Coli, something that was previously thought difficult,” Tomita stated.

Beyond simply producing orsellinic acid, the researchers also demonstrated the potential to synthesize more complex compounds derived from it. They successfully introduced an additional gene from Rhododendron to complete the biosynthesis of grifolic acid, a compound known for its potent anticancer and analgesic properties. While the yield of grifolic acid was currently low, the team acknowledges this as an area for future optimization and has already identified potential bottlenecks in the process.

The implications of this work extend beyond the immediate production of specific drugs. Hasunuma emphasizes that the established platform can be readily adapted to produce a variety of related compounds and their derivatives. “In the short term, the platform established in this study can be immediately applied to the production and evaluation of related compounds and their derivatives,” he explains. “However, the rational design strategy employed here serves as a foundational technology for the production of various complex compounds using E. Coli.”

This research builds on growing interest in leveraging bacterial systems for therapeutic development. Separate research, published in October 2025, highlighted the potential of E. Coli producing 2-methylisocitrate (2-MiCit) to enhance the effectiveness of chemotherapy. Ongoing work explores engineering bacteria for targeted tumor therapy, including surface modification and the creation of synthetic genetic circuits, as detailed in a recent publication in the Journal of Hematological Oncology. These efforts underscore the increasing recognition of bacteria not merely as disease agents, but as potential allies in the fight against cancer and other illnesses.

The Kobe University team’s achievement represents a significant step forward in synthetic biology and pharmaceutical manufacturing. By overcoming the limitations of traditional sourcing methods, they have created a robust and scalable platform for producing valuable drug candidates, potentially accelerating the development of new therapies for a wide range of diseases. The research was supported by funding from the Japan Society for the Promotion of Science and the Japan Science and Technology Agency, and conducted in collaboration with researchers from the University of Minho and the RIKEN Center for Sustainable Resource Science.